| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 09/28/2000 | DE19912850A1 Lösung, insbesondere für Hämo- oder Peritonealdialyse, sowie Verfahren zu deren Herstellung Solution, in particular for hemodialysis or peritoneal dialysis, as well as processes for their preparation |
| 09/28/2000 | CA2371987A1 Screening method involving mgdg synthase |
| 09/28/2000 | CA2368229A1 50 human secreted proteins |
| 09/28/2000 | CA2368223A1 48 human secreted proteins |
| 09/28/2000 | CA2368187A1 Upregulation of type iii endothelial cell nitric oxide synthase by hmg-coa reductase inhibitors |
| 09/28/2000 | CA2368047A1 Chemokine receptor binding heterocyclic compounds |
| 09/28/2000 | CA2367471A1 Fungal beta-tubulin genes |
| 09/28/2000 | CA2367266A1 Gel-microemulsion formulations |
| 09/28/2000 | CA2367025A1 Treatment of lfa-1 associated disorders with increasing doses of lfa-1 antagonist |
| 09/28/2000 | CA2367015A1 Methods of treating tardive dyskinesia and other movement disorders |
| 09/28/2000 | CA2366926A1 Pharmaceutical compositions comprising dipeptidy peptidase iv inhibitors for the promotion of growth |
| 09/28/2000 | CA2366908A1 Vaccine composition |
| 09/28/2000 | CA2366899A1 Oral combinations of hydroxocobalamin and folic acid |
| 09/28/2000 | CA2366650A1 Oral low dose butyrate compositions |
| 09/28/2000 | CA2366613A1 Particle based vaccine composition |
| 09/28/2000 | CA2366555A1 Method for detecting predisposition to a venous thromboembolic disease |
| 09/28/2000 | CA2366552A1 Method for detecting superantigen activity in a biological sample |
| 09/28/2000 | CA2366214A1 Dsp-2 dual-specificity map kinase phosphatase |
| 09/28/2000 | CA2366080A1 Prediction of diabetes impaired wound healing by urinary nitrate assay |
| 09/28/2000 | CA2365405A1 Human tumor necrosis factor receptor-like 2 |
| 09/28/2000 | CA2365255A1 Human tumor necrosis factor receptor tr9 |
| 09/28/2000 | CA2365244A1 Calanolides for inhibiting btk |
| 09/28/2000 | CA2365243A1 Human transmembrane proteins |
| 09/28/2000 | CA2365238A1 48 human secreted proteins |
| 09/28/2000 | CA2365121A1 Antibodies specific for cyp1b1 |
| 09/28/2000 | CA2364687A1 Organ arrest, protection and preservation |
| 09/28/2000 | CA2361221A1 Novel protein which induces chondrocyte differentiation |
| 09/28/2000 | CA2359568A1 The use of certain affinity nmda antagonists as antidepressants |
| 09/27/2000 | EP1038962A1 Peptidoglycan biosynthetic gene murF from Streptococcus pneumoniae |
| 09/27/2000 | EP1038552A2 Solution, in particular a hemodialysis or peritoneal dialysis solution, and method for producing same |
| 09/27/2000 | EP1038533A1 Medicinal compositions for treating immunodeficiency diseases |
| 09/27/2000 | EP1038523A2 Method for identifying compounds for inhibition of neoplastic lesions |
| 09/27/2000 | EP1038520A1 Cosmetics containing meclofenoxate |
| 09/27/2000 | EP1038037A1 Screening assays for the detection and diagnosis of influenza virus |
| 09/27/2000 | EP1038025A1 Genetic alterations associated with cancer |
| 09/27/2000 | EP1038023A1 Agonists of metabotropic glutamate receptors and uses thereof |
| 09/27/2000 | EP1038021A1 Compounds and methods for the inhibition of protein-protein interactions |
| 09/27/2000 | EP1038020A1 Secreted protein nsl4 |
| 09/27/2000 | EP1038019A1 NOVEL ribB |
| 09/27/2000 | EP1038003A1 Cyclic gmp phosphodiesterase |
| 09/27/2000 | EP1038002A1 Ubiquitin-like conjugating protein |
| 09/27/2000 | EP1037995A1 Human interferon-epsilon: a type 1 interferon |
| 09/27/2000 | EP1037993A2 A new gene called oligophrenin 1, its expression product, and the diagnostic and therapeutic applications thereof |
| 09/27/2000 | EP1037984A1 Cadherin-like polypeptides, methods and compositions related thereto |
| 09/27/2000 | EP1037980A1 G-protein coupled receptors associated with immune response |
| 09/27/2000 | EP1037967A2 Human phosphatases |
| 09/27/2000 | EP1037926A1 TREATMENT WITH ANTI-ErbB2 ANTIBODIES |
| 09/27/2000 | EP1037911A1 Anti-pathogen system and methods of use thereof |
| 09/27/2000 | EP1037908A2 Human tumor necrosis factor-r2-like proteins |
| 09/27/2000 | EP1037666A1 Method for enhancing the absorption and transport of lipid soluble compounds using structured glycerides |
| 09/27/2000 | EP1037665A1 Methods and compositions for inhibiting tumor cell growth |
| 09/27/2000 | EP1037661A1 ribH |
| 09/27/2000 | EP1037655A2 Methods of treatment using novel ligands of the neuropeptide receptor hfgan72 and agonists or antagonists thereof |
| 09/27/2000 | EP1037653A1 Compositions and methods for regulating phagocytosis and icam-1 expression |
| 09/27/2000 | EP1037651A1 Small peptides and methods for treatment of asthma and inflammation |
| 09/27/2000 | EP1037649A1 Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents |
| 09/27/2000 | EP1037640A2 Administration of products of the 5-lipoxygenase metabolic pathway to enhance antimicrobial defense |
| 09/27/2000 | EP1037637A1 Use of 5ht1a receptor antagonists for preventing and/or treating temporal lobe epilepsy |
| 09/27/2000 | EP1037636A1 Inhibition of membrane-associated viral replication |
| 09/27/2000 | EP1037629A2 Combination of a retinoic acid metabolism blocking agent and a tocophereol |
| 09/27/2000 | EP1037623A1 Antihyperlipidemic statin-lp(a) inhibitor combinations |
| 09/27/2000 | EP1037621A1 Nitric oxide donor compositions, methods, apparatus, and kits for preventing or alleviating vasoconstriction or vasospasm in a mammal |
| 09/27/2000 | EP1037616A2 Combination of alpha-adrenergic blockers and cgmp levels-elevating compounds effective for the treatment of impotence |
| 09/27/2000 | EP1037529A1 Composition useful for providing one-step surgical preparation and drape |
| 09/27/2000 | EP0575484B1 Composition comprising pdgf and dexamethasone for promoting tissue repair and regeneration |
| 09/27/2000 | CN1268061A Combination of tyrosine kinase inhibitor and chemical castration to treat prostate cancer |
| 09/27/2000 | CN1268059A Thermodynamic adaptive phased array system for activating thermosensitive liposomes in targeted drug delivery |
| 09/27/2000 | CN1268057A Cross-linked polysaccharide drug carrier |
| 09/27/2000 | CN1268056A Use of uridine 5'-diphosphate and analogs thereof for the treatment of lung diseases |
| 09/27/2000 | CN1268054A Combination therapy comprising amlodipine and a statin compound |
| 09/27/2000 | CN1268053A Combination therapy comprising atorvastatin and an antihypertensive agent |
| 09/27/2000 | CN1268050A Pharmaceutical composition for combination of piperidinoalkanol-decongestant |
| 09/26/2000 | US6124362 Topical administration of lupane triterpenes, derivatives of lupane triterpenes, derivatives of oleanane triterpenes, derivatives of ursane triterpenes, and salts |
| 09/26/2000 | US6124337 Treating male impotence by orally ingesting a mixture comprising a disintegrant to accelerate dissolution a phentolamine vasodilator effective within one hour prior to attempting sexual intercourse |
| 09/26/2000 | US6124320 Treating with non-sedating antihistamines without causing cardiac arrhythmias |
| 09/26/2000 | US6124314 Osteoporosis compounds |
| 09/26/2000 | US6124311 Administering oncolytic agent with enhanced multidrug resistance reversing amount of specified compound |
| 09/26/2000 | US6124309 Method and pharmaceutical composition for regulating lipid concentration |
| 09/26/2000 | US6124273 Sustained release wound healing agents |
| 09/26/2000 | US6124263 Treatment of tumors by administration of growth hormone releasing compounds and their antagonists |
| 09/26/2000 | US6124256 Administering an agonist specific for somatostatin (sst) receptor(s) showing an increased expression in the vascular wall subsequent to injury or surgery |
| 09/26/2000 | US6124119 Nucleotide sequences coding enzymatic polypeptide; for the treatment and prevention of bacterial infection; bactericides |
| 09/26/2000 | US6124095 Human nucleotide pyrophosphohydrolase-2 |
| 09/26/2000 | US6123959 Phospholipids, and competitive inhibitor(s) including arbutin of an enzyme for the synthesis of melanin, tyrosinase and non-competitive inhibitor(s) of tyrosinase selected from specified substituted 4-oxo-chromene compounds |
| 09/26/2000 | US6123936 Methods and compositions for the dry powder formulation of interferons |
| 09/26/2000 | US6123662 Cardiac disease treatment and device |
| 09/26/2000 | CA2190011C Method for reduction of headache pain |
| 09/21/2000 | WO2000055634A1 Grb14 and the insulin receptor and screening of novel medicines |
| 09/21/2000 | WO2000055633A2 Methods of screening for colorectal cancer modulators |
| 09/21/2000 | WO2000055620A1 Non-mammalian transgenic animal having an adult onset neurodegenerative phenotype |
| 09/21/2000 | WO2000055351A1 Human colon cancer associated gene sequences and polypeptides |
| 09/21/2000 | WO2000055350A1 Human cancer associated gene sequences and polypeptides |
| 09/21/2000 | WO2000055345A2 Therapy of cancer by insect cells containing recombinant baculovirus encoding genes |
| 09/21/2000 | WO2000055332A2 Human regulators of intracellular phosphorylation |
| 09/21/2000 | WO2000055323A1 Differential expression of organellar gene products |
| 09/21/2000 | WO2000055320A1 Human pancreas and pancreatic cancer associated gene sequences and polypeptides |
| 09/21/2000 | WO2000055318A2 Abc1 polypeptide and methods and reagents for modulating cholesterol levels |
| 09/21/2000 | WO2000055201A1 49 human secreted proteins |
| 09/21/2000 | WO2000055180A2 Human lung cancer associated gene sequences and polypeptides |
| 09/21/2000 | WO2000055174A1 Human prostate cancer associated gene sequences and polypeptides |